PharmaEssentia Corporation — Investor Relations & Filings
PharmaEssentia Corporation is a fully integrated global entity focused on the discovery, development, and commercialization of novel therapies for hematologic diseases and oncology. The company leverages a proprietary PEGylation technology platform to engineer long-acting protein therapeutics designed to improve patient outcomes. Its flagship product, BESREMi® (Ropeginterferon alfa-2b), represents a significant advancement in the treatment of Polycythemia Vera, having received regulatory approval from the US FDA and EU EMA as a first-line therapy. PharmaEssentia operates a comprehensive value chain, including internal R&D, clinical trial management, and cGMP-certified manufacturing facilities. By addressing unmet medical needs in rare blood disorders and various cancers, the company aims to deliver best-in-class treatments to global markets through its integrated research and production capabilities.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 本公司新藥BESREMi（Ropeginterferon alfa-2b）獲 衛福部使用於原發性血小板過多症（ET）核准函 | 2026-05-12 | Chinese | |
| 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | |
| 115年04月董事會成員及持股 | 2026-05-05 | Chinese | |
| 本公司就撤仲案向德國聯邦最高法院提出上訴 | 2026-05-03 | Chinese | |
| 本公司受邀參加永豐金證券舉辦之法人說明會 | 2026-04-30 | Chinese | |
| 115年05月法人說明會簡報 | 2026-04-30 | Chinese |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46203480 | 本公司新藥BESREMi（Ropeginterferon alfa-2b）獲 衛福部使用於原發性血小板過多症（ET）核准函 | 2026-05-12 | Chinese | ||
| 41459336 | 115年04月內部人持股異動(事後) | 2026-05-05 | Chinese | ||
| 41456974 | 115年04月董事會成員及持股 | 2026-05-05 | Chinese | ||
| 40262270 | 本公司就撤仲案向德國聯邦最高法院提出上訴 | 2026-05-03 | Chinese | ||
| 39868460 | 本公司受邀參加永豐金證券舉辦之法人說明會 | 2026-04-30 | Chinese | ||
| 39868469 | 115年05月法人說明會簡報 | 2026-04-30 | Chinese | ||
| 38341454 | 115年4月28日內部人設質解質 | 2026-04-29 | Chinese | ||
| 37414903 | 115年年報及股東會資料 — 2026_6446_20260528F13.pdf | 2026-04-27 | Chinese | ||
| 37414833 | 115年年報及股東會資料 — 2026_6446_20260528FE1.pdf | 2026-04-27 | English | ||
| 37414808 | 115年年報及股東會資料 — 2026_6446_20260528F01.pdf | 2026-04-27 | Chinese | ||
| 37415357 | 115年年報及股東會資料 — 2026_6446_20260528FE2.pdf | 2026-04-27 | English | ||
| 37415315 | 115年年報及股東會資料 — 2026_6446_20260528F02.pdf | 2026-04-27 | Chinese | ||
| 36876006 | 說明本公司撤仲案進度 | 2026-04-26 | Chinese | ||
| 35221775 | 公告本公司台中廠已獲越南衛生部藥品管理局（DAV） 認定通過優良製造規範（GMP） | 2026-04-22 | Chinese | ||
| 33966999 | 媒體報導說明 | 2026-04-10 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Beijing SL Pharmaceutical Co., Ltd.
Develops and manufactures drugs for cardiovascular, oncolog…
|
002038 | CN | Manufacturing |
|
Beijing Strong Biotechnologies, Inc
Develops and manufactures IVD products, clinical chemistry …
|
300406 | CN | Manufacturing |
|
Beijing Tiantan Biological Products Corporation Limited
Researches and produces plasma-derived medicinal products a…
|
600161 | CN | Manufacturing |
|
Beijing Tong Ren Tang Chinese Medicine Company Limited
A manufacturer and retailer of traditional Chinese medicine…
|
3613 | HK | Manufacturing |
|
BEIJING TONG REN TANG CO., LTD
Researches, manufactures, and distributes Traditional Chine…
|
600085 | CN | Manufacturing |
|
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Develops and manufactures IVD reagents and vaccines for inf…
|
603392 | CN | Manufacturing |
|
Beleave Inc.
Vertically integrated cannabis company engaged in cultivati…
|
BLEVF | CA | Manufacturing |
|
BELITE BIO, INC
Clinical-stage biopharma developing therapies for retinal a…
|
BLTE | KY | Manufacturing |
|
Benitec Biopharma Inc.
A clinical-stage biotech developing genetic medicines to si…
|
BNTC | US | Manufacturing |
|
BeOne Medicines Ltd.
Global oncology company that discovers, develops, and deliv…
|
ONC | KY | Manufacturing |
PharmaEssentia Corporation via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52565/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52565 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52565 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52565 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52565}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaEssentia Corporation (id: 52565)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.